PR83475

AMERSHAM, United Kingdom, Apr. 1, 2020 /PRNewswire=KYODO JBN/--

- New Danaher operating company created following completion of $21.4B

acquisition by Danaher Corporation

- Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth

and innovation in biological therapies

- Leading life sciences brands such as AKTA, Amersham, HyClone, MabSelect and

Whatman are part of Cytiva

Cytiva, a global provider of technologies and services that help advance and

accelerate the development and manufacture of therapeutics, launches today.

Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and

operations in 40 countries and is part of the Danaher Corporation Life Sciences

platform.

Logo - https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg

Emmanuel Ligner, President of Cytiva, says: "Our foundation of scientific

expertise, our team, and our solid customer base place Cytiva in the right

position to invest, develop, and accelerate growth in the industry. Our passion

for helping bring life-changing therapies to patients is unwavering, and we

will continue to introduce innovative technologies to the market which improve

productivity for our customers."

Cytiva experts and technologies enabled breakthroughs in science and medicine

that have shaped today's biotechnology industry. In 2019, more than 75 percent

of the biological therapies approved by the United States Food and Drug

Administration relied on Cytiva's technologies for manufacturing. Additionally,

Cytiva technology has contributed in the nascent area of cell and gene

therapies and has done so since the first successful pediatric trial of CAR-T

therapy in 2012. This area continues to have great potential and currently,

there are more than 1,000 regenerative medicine clinical trials underway

globally[1].

Accelerating growth, productivity, and innovation in the sector are major

strategic focus areas for the company, as global demand for personalized and

advanced biological therapies is ever-increasing. Cytiva drives

customer-centered innovation, from idea to commercial development stages, with

facilities across Asia, Europe, and the Americas. It also has centers for

customer collaboration and training to enable the development of new therapies,

such as the Testa Center in Uppsala, Sweden and with the University of

Technology at Sydney.

Cytiva will also continue to pursue collaborations for research, such as the

center for advanced biological innovation and manufacturing in Boston with

Harvard, MIT, teaching hospitals, and industry partners Fujifilm Diosynth

Biotechnologies, and Alexandria Real Estate Equities, Inc.

Cytiva's diverse portfolio includes well-recognized brands such as AKTA,

Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex

and Xuri. The portfolio spans a full range of instruments, consumables, digital

and enterprise solutions and services for research, process development, and

complete manufacturing workflows that scale according to customers' needs.

About Cytiva

Cytiva is a 3.3 billion USD global life sciences leader with nearly 7000

associates operating in 40 countries dedicated to advancing and accelerating

therapeutics. As a trusted partner to customers that range in scale and scope,

Cytiva brings speed, efficiency and capacity to research and manufacturing

workflows, enabling the development, manufacture and delivery of transformative

medicines to patients. Visit www.cytiva.com for more.

[1] The Alliance for Regenerative Medicine Q3 2019 Quarterly Report (

https://c212.net/c/link/?t=0&l=en&o=2762961-1&h=2991931794&u=https%3A%2F%2Falliancerm.org%2Fpublication%2Fq3-2019-data-report%2F&a=The+Alliance+for+Regenerative+Medicine+Q3+2019+Quarterly+Report

)

SOURCE: Cytiva

CONTACT: Dodi Axelson

Dodi.axelson@ge.com

+46730958191